


Over a Decade of Award-Winning Excellence in Supporting Academic Research

For nearly a decade, ChromaDex has invested in cellular health research by supplying high quality and patented research materials, providing technical expertise, and commercializing the inventions of independent scientists around the world.

ChromaDex is the main owner and licensee of intellectual property for nicotinamide riboside (NR). In collaboration with our strategic partners, we manufacture NR as both an ingredient (NIAGEN®) and a finished dietary supplement product (TRU NIAGEN®) to the highest quality and standards.

As a result, we have received regulatory acceptance* in the United States, Canada, Australia, Europe, and Brazil.



The ChromaDex External Research Program (CERP™)

Setting the Industry Standard for Excellence in Collaborative Research

Since its founding in 2013, the ChromaDex External Research Program (CERP™) has supplied NIAGEN®, novel NAD+ precursors, isotopically labeled compounds, and other ChromaDex material for preclinical and clinical research. Our team of scientists can share their analytical and regulatory expertise to support your successful design and execution of high-impact studies using these molecules. Applications are accepted on a rolling basis.

Please use the QR code below, or go to www.chromadex.com/cerp for more information.

275+

Research Collaborations

NIAGEN® has been independently researched by teams at Chiba University, Haukeland University Hospital, Cambridge University, Duke University, Massachusetts General Hospital, Northwestern University, Harvard Medical and many more around the world.

125+

Published Preclinical Studies

Many peer-reviewed published studies have investigated the effects of NIAGEN® on cells, mice, and other model organisms to help scientists understand the cellular and physiological effects of replenishing NAD+.

25+

Published Clinical Studies

The safety and efficacy of NIAGEN® has been studied in multiple peer-reviewed clinical studies, with more than 35 additional studies currently registered at: www.clinicaltrials.gov.

CERP Research Published in High-Impact Journals

Science Advances

Lapatto et al. (2023). Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study.

Cell Metabolism

Brakedal et al. (2022). The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.

J of Clinical Investigation

Wu, et al. (2022). Boosting NAD+ blunts toll-like receptor-4 induced type-I interferon in control and systemic lupus erythematosus monocytes.

To view a complete list of all CERP publications please use the QR code above.


Your Partner in Scientific Discovery

ChromaDex, Inc.

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA 90034
(888) 642-4361 | cerp@chromadex.com | www.chromadex.com/cerp



Invested in Innovation



ChromaDex Scientific Advisory Board



Dr. Charles Brenner



Dr. Rudolph Tanzi




Sir John Walker FRS, FMedSci



Dr. Bruce German



Dr. David L. Katz, M.D., M.P.H.,
FACPM, FACP, FACLM



Dr. Roger Kornberg



Dr. Brunie H. Felding



Dr. Vilhelm (Will) Bohr, M.D.,
Ph.D., D.Sc.

Talk to us about how we can support your inventorship and patent protection domestically and globally.

When you patent your work, your institution can license it to other organizations who can then commercialize it and put it to use in the marketplace. This generates licensing and royalty fees for you as the inventor.

ChromaDex vigorously supports and defends inventorship and the academic institutions where the work is performed. Over the past several years, ChromaDex has invested millions in licensing fees and millions more prosecuting defense of this important intellectual property.

*Public Regulatory Acceptance for NIAGEN® and TRU NIAGEN® can be found at: <http://pages.truniagen.com/regulatory>

**Patents for other ChromaDex ingredients can be provided upon request.

AS FEATURED ON

Forbes

WINNER
NUTRA
INGREDIENTS
AWARDS 2022



Nutritional Outlook's
2019 Best of the Industry:
Ingredient Supplier

ChromaDex, Inc.

10900 Wilshire Boulevard, Suite 600, Los Angeles, CA 90034
(888) 642-4361 | cerp@chromadex.com | www.chromadex.com/cerp

Updated June 2023